Strategic Launch Report

Predict Payer Uptake
Of New Drugs With Precision

MMIT Strategic Launch Report provides drug manufacturers with a realistic view of payers’ coverage adoption rates and utilization management within the first year post-launch.The report is paired with consensus forecast data from our partner, Evaluate, for currently approved and pipeline agents within the target indication, to help you identify competitors and challenges and proactively plan your near- and long-term strategies.

Use Strategic Launch Report & Evaluate Forecast to:

Predict one-year uptake of a pipeline agent
Outline payer and channel segmentation and identify slow and more restrictive payers and PBMs across various channels
Perform launch scenario analysis for appropriate analogs to identify what led to their respective uptake curves

Learn More About Strategic Launch Report & Evaluate Forecast

Strategic Launch Report & Evaluate Forecast Can Help Commercial Teams

Highlight potential obstacles from new drug launch policies
Inform speed of decision-making
Correlate analogs’ policy uptake with sales volumes to get a complete picture and set realistic launch expectations
Identify scenarios when agents with more restrictive or slow policy uptake still experienced sales uptake or vice versa
Through color commentary from Evaluate and MMIT syndicated reports, understand the reasoning behind what payer did vs. what physicians did

diverse-businesspeople-laughing-while-working-together

strategic-launch-report-product-screenshots

Evaluate and MMIT united in August 2021 to offer customers a unique and comprehensive data solution offering both analytical and predictive data insights across the entire drug life cycle. London-based Evaluate is a leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry.